The Ventech team is please to announce the final closing of its third fund, Ventech Capital III, which raised €150 million in accordance with the objectives announced at its launch.

Ventech Capital III, which is sponsored by Natixis Private Equity, has attracted numerous prestigious investors, including AGF, CDC Entreprises, Groupe Caisse d’Epargne and Société Générale. Note that more than half the funds raised were contributed by new investors, acknowledgment by the asset management industry of the Ventech team’s performances. .

Ventech Capital III – which has already invested in six companies, including Actogenix (administration of therapeutic proteins and peptides), Crocus Technology (magnetic random access memories), Mxp4 (interactive digital music format), Skyrecon (security software solutions) and Viadeo (internet platform for professional networking) – will invest in the Information Technology sector (60% spread between Hardware Communication, Software and Technology-enable Services) and in Biotechnology (40%), mainly in Continental Europe.

With this third investment vehicle, Ventech now manages over €325 million of funds, with Ventech Capital I and Ventech Capital II having raised and invested respectively €62 million and €112 million. Since its creation, Ventech has established a solid track record, with an average multiple of 3x on exits, including notably the initial public offering of Meilleurtaux (the first company listed on the Paris Alternext, multiple of 16x) plus the acquisitions of Musiwave ($120 million, 10x) and Alantos Pharmaceuticals ($300 million, 5.5x).
Other key divestments completed by Ventech include, Altitude, Calendra, Evotec Neurosciences, Genesys, Internext, K-Mobile, Virtools and Sterilyo.

Global Private Equity acted as Ventech’s placement agent.